Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $22.7 million.

  • Arrowhead Pharmaceuticals' Capital Expenditures fell 69.03% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year decrease of 83.95%. This contributed to the annual value of $22.7 million for FY2025, which is 83.95% down from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Capital Expenditures of $22.7 million as of FY2025, which was down 83.95% from $141.5 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' Capital Expenditures' 5-year high stood at $176.7 million during FY2023, with a 5-year trough of $22.7 million in FY2025.
  • Moreover, its 3-year median value for Capital Expenditures was $141.5 million (2024), whereas its average is $113.6 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Capital Expenditures surged by 234.88% in 2023, and later tumbled by 83.95% in 2025.
  • Arrowhead Pharmaceuticals' Capital Expenditures (Yearly) stood at $23.6 million in 2021, then soared by 123.94% to $52.8 million in 2022, then surged by 234.88% to $176.7 million in 2023, then fell by 19.96% to $141.5 million in 2024, then tumbled by 83.95% to $22.7 million in 2025.